Healthcare Private Placement and M&A Transactions Review Week Ending July 20, 2025

OpenEvidence: The company raised $210 million of Series B venture funding in a deal led by GV and Kleiner Perkins on July 15, 2025, putting the company’s pre-money valuation at $3.29 billion. Coatue Management, Conviction Partners, Sequoia Capital, and Thrive Capital also participated in the round. The company is a developer of an AI-powered information platform intended to organize medical knowledge and make it more useful, open, accessible, and understandable.

Numan: The company raised GBP 74.7 million of venture funding through a combination of debt and equity on July 16, 2025, putting the company’s pre-money valuation at GBP 105.06 million. GBP 60 million of Series B venture funding was led by Big Pi Ventures with the participation from HFT Investment Management Co., Keros Capital, HSBC Innovation Banking, Novator Partners, VNV Global, Colle Capital Partners, White Star Capital, Paul Heydon, Anthemis, Hanwha Asset Management and Endeavor Catalyst. GBP 14.7 million of the debt financing in the form of a loan was provided by Kreos Capital. The company is an operator of a digital healthcare platform intended to address weight loss, erectile dysfunction and other health conditions.

EndoQuest Robotics: The company raised an estimated $59 million of Series D venture funding in a deal led by Crescent Enterprises Invests and Fred Moll on July 14, 2025, putting the company’s pre-money valuation at $260 million. Puma Venture Capital, The University of Texas Health Science Center and other undisclosed investors also participated in the round. The company is a developer of flexible robotic devices designed to perform procedures in the body using the natural lumens, and operating scar-free.

Fellow: The company raised $24 million of Series B venture funding in a deal led by 5AM Ventures on July 16, 2025, putting the company’s pre-money valuation at $51 million. The Forest Road Company and other undisclosed investors also participated in the round. The company is a provider of mail-in semen analysis, vasectomy tests and cryopreservation services.

KORTUC: The company raised $20 million of Series B venture funding in a deal led by Midas Capital on July 15, 2025. The company is a developer of a novel radiosensitizer designed to enhance the efficacy of cancer radiotherapy.

Tulavi Therapeutics: The company raised $20 million of Series C venture funding from Greenwave Ventures (Florida) and other undisclosed investors on July 15, 2025, putting the company’s pre-money valuation at $63 million. The company is a medical device business focused on developing innovative solutions for nerve repair and protection, particularly in peripheral nerve surgery.

BiomEdit: The company raised $18.6 million of Series B venture funding from Nutreco, Betagro Ventures and Elevate Ventures on July 15, 2025. Anterra Capital and AgriZeroNZ also participated in the round. The company is a developer of a microbiome innovation platform designed to discover and develop animal health products.

One Biosciences: The company raised EUR 15 million of Series A venture funding in a deal led by Redmile Group and Blast.Club on July 17, 2025. Adamed Pharma, The Invus Group, Sofinnova Partners, Polytechnique Ventures, Kima Ventures and Galion.exe also participated in the round. The company is a developer of AI-powered single-cell diagnostic technology designed to integrate functional tumor profiling into clinical practice.

Nia Therapeutics: The company raised $15.6 million of venture funding from Ben Franklin Technology Partners, Paeonia Group and other undisclosed investors on July 17, 2025. The company is a developer of a neurostimulation device designed to reactivate memory for patients with traumatic brain injury.

CoreMap: The company raised $6.8 million of venture funding from undisclosed investors on July 14, 2025. The company is a developer of advanced diagnostic technology for electrophysiologists and patients, in the area of atrial fibrillation.

Daphos: The company raised EUR 5 million of venture funding from OÖ HightechFonds, YZR Capital and Venture Stars on July 17, 2025. D11Z.Ventures and PUSH Ventures also participated in the round. The company is a developer of a health workforce management system designed to offer personnel, resource, and process management services for healthcare facilities.

Cyrus Biotechnology: The company raised $4.3 million of venture funding from New Dimensions Health and Anzu Partners and other undisclosed investors on July 15, 2025. The company is an operator of a biologic therapeutics company intended to treat serious diseases through advanced protein engineering.

Blueprint Medicines / Sanofi: The company was acquired by Sanofi for $9.5 billion on July 18, 2025. Blueprint Medicines Corp is a biopharmaceutical company developing medicines for allergy, inflammation, oncology, and hematology.

23andMe / TTAM Research Institute: The company was acquired by TTAM Research Institute for $305 million on July 14, 2025. 23andMe Holding Co is a consumer-facing healthcare technology company, involved in the sale of direct-to-consumer personal genome services, or PGS, through mail-in DNA collection kits.

Monogram Technologies / Zimmer Biomet Holdings: The company reached a definitive agreement to be acquired by Zimmer Biomet Holdings for $177 million on July 14, 2025. Monogram Technologies Inc provides patient-optimized orthopedic implants at scale by linking 3D printing and robotics with pre-operative imaging.

KeriMedical / Medartis: The company reached a definitive agreement to be acquired by Medartis for CHF 99 million on July 17, 2025. The company is a manufacturer of orthopedic and prosthetic implants and devices for hand and wrist surgery.

iCAD / DeepHealth: The company was acquired by DeepHealth, a subsidiary of RadNet, for $100 million on July 17, 2025. icad Inc is a medical technology company providing cancer detection and therapy solutions.

CareMates / myneva Group: The company was acquired by myneva Group, via its financial sponsor Summa Equity, through an LBO on July 18, 2025 for an undisclosed amount. The company is a provider of AI-powered patient admission CRM software intended to significantly reduce the administrative burden for eldercare providers in Germany.

DiamiR Biosciences / Aptorum Group: The company reached a definitive agreement to acquire Aptorum Group through a reverse merger, resulting in the combined entity trading on the NASDAQ on July 16, 2025. Diamir Biosciences Corp is a molecular diagnostic company engaged in developing noninvasive tests for early detection and monitoring of Mild Cognitive Impairment, Alzheimer’s, and Parkinson’s.

DignifiHealth / Sellers, Dorsey & Associates: The company was acquired by Sellers, Dorsey & Associates, via its financial sponsor Consonance Capital, through an LBO on July 14, 2025 for an undisclosed amount. The company is a provider of value-based care solutions within the healthcare sector, focusing on population health management.

ESSA / XenoTherapeutics: The company reached a definitive agreement to be acquired by XenoTherapeutics for an undisclosed amount as of July 14, 2025. ESSA Pharma Inc is a pharmaceutical company focused on the development of small-molecule drugs for the treatment of castration-resistant prostate cancer.

Gentell ManukaMed / Gentell: The company was acquired by Gentell, via its financial sponsors Cane Investment Partners, Perigrove and Pinta Capital Partners, through an LBO on July 14, 2025for an undisclosed amount. The company is a manufacturer of honey-based wound dressings.

MOD3 Pharma / AptarGroup: The company was acquired by AptarGroup for an undisclosed amount on July 15, 2025. The company is a developer of oral dosage formulations intended for peptides and small-molecule therapeutics.

Ocuvex Therapeutics / Onconetix: The company reached a definitive agreement to be acquired by Onconetix for an undisclosed amount on July 16, 2025. The company is a manufacturer of ophthalmic therapeutic candidates.